Holen Sie sich die Stockscreener-App
0.762
8.19%
-0.068
Handel nachbörslich:
.76
-0.002
-0.26%
Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements - marketscreener.com
NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC - TipRanks
NeuroSense Granted Brazilian Patent Covering PrimeC Composition - Bitget
Brazil grants NeuroSense (NRSN) patent protecting PrimeC ALS and Alzheimer’s drug - stocktitan.net
Brazil grants NeuroSense ALS drug patent protection through 2042 - stocktitan.net
If You Invested $1,000 in Neurosense Therapeutics Ltd (NRSN) - stocktitan.net
NRSN PE Ratio & Valuation, Is NRSN Overvalued - Intellectia AI
NeuroSense Therapeutics Ltd. (NRSN) stock price, news, quote and history - Yahoo Finance UK
NeuroSense Therapeutics Receives Nasdaq Notifications on Compliance Issues - National Today
NeuroSense Faces Nasdaq Compliance Warning - Intellectia AI
NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status - TipRanks
Nasdaq flags NeuroSense (NRSN) for bid price and $35M value shortfall - stocktitan.net
NeuroSense Therapeutics Ltd. Stock Forecast Summary - Meyka
NRSN’s $1.00 Bid Price Requirement Serves as Key Trigger for Meeting Compliance and Raising Capital - Bitget
Roth MKM Maintains NeuroSense Therapeutics(NRSN.US) With Buy Rating, Maintains Target Price $3 - Moomoo
NeuroSense (NRSN) CFO awarded 200,000 restricted shares vesting over 2 years - stocktitan.net
NeuroSense (NRSN) CFO Or Eisenberg reports 573,126 shares and warrants on Form 3 - stocktitan.net
Free cash flow per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
NeuroSense Therapeutics Posts 2025 Results as PrimeC Advances Toward Phase 3 ALS Trial - TipRanks
NeuroSense Therapeutics (NRSN) director details options and restricted shares - stocktitan.net
NeuroSense (NRSN) 2025 20-F: cash squeeze, going concern and PrimeC ALS plans - Stock Titan
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update - PR Newswire
Market Pulse: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2026 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
NeuroSense (NRSN) CTO awarded 200,000 restricted shares vesting over two years - stocktitan.net
NeuroSense (NASDAQ: NRSN) CTO discloses options, shares and RSU awards - stocktitan.net
NeuroSense (NRSN) CEO details substantial share and warrant holdings - stocktitan.net
NeuroSense Therapeutics (NASDAQ: NRSN) grants GM Hagit Binder 200,000 shares - stocktitan.net
Risk Report: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergence2026 Major Catalysts & AI Driven Price Predictions - baoquankhu1.vn
NeuroSense Therapeutics (NASDAQ:NRSN) Receives “Buy” Rating from D. Boral Capital - Defense World
Market Fear: What are NeuroSense Therapeutics Ltd Equity Warrants recent SEC filings showingEarnings Recap Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
NeuroSense Therapeutics (NRSN): Analyst Reaffirms 'Buy' Rating | - GuruFocus
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout - Finviz
NeuroSense Reschedules Health Canada Meeting as PrimeC Data Package Strengthens - TipRanks
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer) | NRSN SEC FilingForm 6-K - Stock Titan
NeuroSense Advances Toward Key Regulatory Milestones With Strengthened Data Package and Near-Term Alzheimer's Readout - 富途牛牛
Chart Watch: Is NeuroSense Therapeutics Ltd in a consolidation phase2026 Analyst Calls & Verified Technical Trade Signals - baoquankhu1.vn
NRSN SEC FilingsNeurosense Therapeutics Ltd 10-K, 10-Q, 8-K Forms - stocktitan.net
NeuroSense Therapeutics Ltd.: Fundamental Analysis and Financial Ratings | H1Z | IL0011809592 - marketscreener.com
NeuroSense (NRSN) director Pellizzari details option and share holdings - Stock Titan
NeuroSense Therapeutics (NRSN) CMO details option and warrant holdings - Stock Titan
NeuroSense (NRSN) director details options and restricted share holdings - Stock Titan
NeuroSense (NRSN) GM Hagit Binder details share, option and RSU holdings - Stock Titan
/C O R R E C T I O N -- NeuroSense/ - PR Newswire
Bull Bear: What are NeuroSense Therapeutics Ltd Equity Warrants recent SEC filings showingStop Loss & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference - GuruFocus
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
Neurosense Therapeutics Ltd - Reuters
PrimeC New Data to Be Presented at AD/PD 2026 Conference - Finviz
NeuroSense Therapeutics (NRSNW) Projected to Post Quarterly Earnings on Wednesday - Defense World
Director at NeuroSense (NASDAQ: NRSN) discloses equity awards and vesting - Stock Titan
EPS Watch: Whats the fair value of NeuroSense Therapeutics Ltd stock2026 Top Gainers & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Is United Therapeutics Corporation gaining market share2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
Aug Opening: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2026 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
Breakout Watch: Will NeuroSense Therapeutics Ltd Equity Warrant benefit from green energy policiesTrend Reversal & Consistent Return Investment Signals - baoquankhu1.vn
FOMO Trade: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergence2026 Top Gainers & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Published on: 2026-03-17 06:01:38 - baoquankhu1.vn
NeuroSense’s ALS Drug PrimeC Shows Strong Phase 2b Results in JAMA Neurology - TipRanks
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer) - Stock Titan
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity - PR Newswire
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):